Gsk (GSK) Change in Receivables (2009 - 2017)
Gsk (GSK) posted quarterly Change in Receivables of -$381.0 million for Q4 2017, down 63.03% year-over-year from -$1.0 billion in Q4 2016, and down 63.03% quarter-over-quarter from -$233.7 million in Q4 2016.
Gsk (GSK) Change in Receivables (2009 - 2017) Analysis & Trends
Gsk's Change in Receivables history runs 9 years deep, the most recent figure standing at -$381.0 million for Q4 2017.
- In Q4 2017, Change in Receivables fell 63.03% year-over-year to -$381.0 million; the TTM figure through Dec 2017 stood at $83.7 million (down 82.93% YoY), while the FY2018 annual figure was -$573.0 million, down 54.97% from the prior year.
- Change in Receivables for Q4 2017 stood at -$381.0 million, down from -$233.7 million in the prior quarter.
- The five-year high for Change in Receivables was $549.8 million in Q4 2014, with the low at -$381.0 million in Q4 2017.
- The 5-year median for Change in Receivables is $25.9 million (2013), against an average of $21.9 million.
- The sharpest annual moves came in 2014 and 2016: Change in Receivables jumped 2022.31% in 2014, then tumbled 257.16% in 2016.
- Gsk's Change in Receivables stood at $25.9 million in 2013, then surged by 2022.31% to $549.8 million in 2014, then slumped by 72.95% to $148.7 million in 2015, then sank by 257.16% to -$233.7 million in 2016, then sank by 63.03% to -$381.0 million in 2017.
- Business Quant data shows GSK's Change in Receivables at -$381.0 million in Q4 2017, -$233.7 million in Q4 2016, and $148.7 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -381.04 Mn |
| Dec 31, 2017 | -381.04 Mn |
| Dec 31, 2016 | -233.73 Mn |
| Dec 31, 2016 | -233.73 Mn |
| Dec 31, 2015 | 148.71 Mn |
| Dec 31, 2015 | 148.71 Mn |
| Dec 31, 2014 | 549.79 Mn |
| Dec 31, 2014 | 549.79 Mn |
| Dec 31, 2013 | 25.91 Mn |
| Dec 31, 2013 | 25.91 Mn |
| Dec 31, 2012 | 293.87 Mn |
| Dec 31, 2012 | 293.87 Mn |
| Dec 31, 2011 | 301.74 Mn |
| Dec 31, 2011 | 301.74 Mn |
| Dec 31, 2010 | 1.43 Bn |
| Dec 31, 2010 | 1.43 Bn |
| Dec 31, 2009 | -772.64 Mn |
| Dec 31, 2009 | -772.64 Mn |